Subacute Cutaneous Lupus Erythematosus (SCLE) Treatment & Management
- Author: Jeffrey P Callen, MD; Chief Editor: William D James, MD more...
Approach Considerations
The goals of management in subacute cutaneous lupus erythematosus (SCLE) are to improve the patient's appearance and to prevent the development of additional lesions. Counsel patients regarding the risk of serious systemic disease. Traditionally, it was suggested that although many patients fulfilled the criteria for SLE, the severity of systemic manifestations was mild, and renal and central nervous system (CNS) disease rarely occurred.
Cohen and Crosby found no appreciable difference between SCLE and SLE patients seen in a rheumatology practice,[10] whereas Black et al found significant differences between these 2 populations.[11] Inform patients that although they probably will not have serious systemic disease, follow-up evaluation and treatment will be performed for manifestations that may occur.
Surgical approaches rarely are needed in patients with SCLE. Also, cosmetic measures are less important in patients with this condition than in patients with DLE. No special diet is required with SCLE.
Inpatient care
Inpatient care is rarely needed for patients with skin disease; however, since these patients may have SLE, they may occasionally manifest internal complications that require hospitalization. In these instances, consultation with other physicians may be helpful.
Skin Protection
Therapy begins with sun-protective measures, including sunscreens, protective clothing, and behavior alteration. A sunscreen containing Mexoryl SX and Mexoryl XL, tested in a randomized, placebo-controlled trial, was demonstrated to prevent the development of UV-induced cutaneous lesions.[12, 13]
Another study demonstrated that in an experimental setting, CLE can be prevented by the use of a particular broad-spectrum sunscreen. The use of sunscreens in a clinical setting is not as effective as would be predicted from studies such as this one, perhaps because patients do not perform sunscreen application on a daily basis in a manner that might be effective.[14]
Pharmacologic Therapy
Standard therapy includes corticosteroids (topical, intralesional) and antimalarials. Additional therapies that may be considered in selected patients include auranofin, dapsone, thalidomide, retinoids, interferon, and immunosuppressive agents.[15, 16, 17]
Avoid systemic corticosteroids except for acute short-term usage or when the presence of systemic disease warrants use. Patients who smoke appear to respond less well to antimalarial therapy. Note that clofazimine is primarily beneficial for cutaneous, not systemic, disease.
Some patients with cutaneous LE have been found to be vitamin D deficient; therefore, the use of vitamin D and calcium should be considered following an assessment of vitamin D levels.[18]
Consultations
Consultations with the following specialists may be helpful:
- Rheumatologist - When joints are involved
- Nephrologist - When renal involvement is present
- Neurologist - When CNS disease is present
- Internal medicine specialist - For systemic involvement
- Ophthalmologist – Many patients will be treated with antimalarials and such patients need periodic ocular evaluations
Long-Term Monitoring
Follow patients with subacute cutaneous lupus erythematosus (SCLE) at regular intervals. Response to therapy varies, depending on the therapeutic agent prescribed. Avoid changes in therapy until a sufficient period elapses to note a response.
At least once each year, and perhaps twice, assess stable patients using routine laboratory tests, including complete blood count (CBC), renal function tests, and urinalysis. Repeat autoantibody testing is of little use in patients with SCLE, unless they have SLE. In patients with SLE, serial anti-nDNA antibody testing may predict the course of the disease. Regularly assess historical information concerning additional systemic manifestations.
Klein LR, Elmets CA, Callen JP. Photoexacerbation of cutaneous lupus erythematosus due to ultraviolet A emissions from a photocopier. Arthritis Rheum. Aug 1995;38(8):1152-6. [Medline].
Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med. Jul 1985;103(1):49-51. [Medline].
Bentley DD, Graves JE, Smith DI, Heffernan MP. Efalizumab-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol. May 2006;54(5 Suppl):S242-3. [Medline].
Bezerra EL, Vilar MJ, da Trindade Neto PB, Sato EI. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum. Oct 2005;52(10):3073-8. [Medline].
Cassis TB, Callen JP. Bupropion-induced subacute cutaneous lupus erythematosus. Australas J Dermatol. Nov 2005;46(4):266-9. [Medline].
Farhi D, Viguier M, Cosnes A, Reygagne P, et al. Terbinafine-induced subacute cutaneous lupus erythematosus. Dermatology. 2006;212(1):59-65. [Medline].
Lowe G, Henderson CL, Grau RH, Hansen CB, Sontheimer RD. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol. Mar 2011;164(3):465-72. [Medline].
Durosaro O, Davis MD, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study. Arch Dermatol. Mar 2009;145(3):249-53. [Medline].
Schmitt V, Meuth AM, Amler S, Kuehn E, Haust M, Messer G, et al. Lupus erythematosus tumidus is a separate subtype of cutaneous lupus erythematosus. Br J Dermatol. Jul 7 2009;[Medline].
Cohen MR, Crosby D. Systemic disease in subacute cutaneous lupus erythematosus: a controlled comparison with systemic lupus erythematosus. J Rheumatol. Sep 1994;21(9):1665-9. [Medline].
Black DR, Hornung CA, Schneider PD, Callen JP. Frequency and severity of systemic disease in patients with subacute cutaneous lupus erythematosus. Arch Dermatol. Sep 2002;138(9):1175-8. [Medline].
Herzinger T, Plewig G, Rocken M. Use of sunscreens to protect against ultraviolet-induced lupus erythematosus. Arthritis Rheum. Sep 2004;50(9):3045-6. [Medline].
Stege H, Budde MA, Grether-Beck S, Richard A, Rougier A, Krutmann J. Evaluation of the capacity of sunscreens to photoprotect lupus erythematosus patients by employing the photoprovocation test. Eur J Dermatol. Jul-Aug 2002;12(4):VII-IX. [Medline].
Kuhn A, Gensch K, Haust M, Meuth AM, Boyer F, Dupuy P, et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J Am Acad Dermatol. Jan 2011;64(1):37-48. [Medline].
Housman TS, Jorizzo JL, McCarty MA, Grummer SE, Fleischer AB Jr, Sutej PG. Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus. Arch Dermatol. Jan 2003;139(1):50-4. [Medline].
Sticherling M, Bonsmann G, Kuhn A. Diagnostic approach and treatment of cutaneous lupus erythematosus. J Dtsch Dermatol Ges. Jan 2008;6(1):48-59. [Medline].
Usmani N, Goodfield M. Efalizumab in the treatment of discoid lupus erythematosus. Arch Dermatol. Jul 2007;143(7):873-7. [Medline].
Cusack C, Danby C, Fallon JC, et al. Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus. Photodermatol Photoimmunol Photomed. Oct 2008;24(5):260-7. [Medline].
James JA, Kim-Howard XR, Bruner BF, Jonsson MK, McClain MT, Arbuckle MR, et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus. 2007;16(6):401-9. [Medline].
Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman DD, Urowitz M, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. Mar 2010;62(3):863-8. [Medline].
Callen JP, Klein J. Subacute cutaneous lupus erythematosus. Clinical, serologic, immunogenetic, and therapeutic considerations in seventy-two patients. Arthritis Rheum. Aug 1988;31(8):1007-13. [Medline].
Callen JP. Management of "refractory" skin disease in patients with lupus erythematosus. Best Pract Res Clin Rheumatol. Oct 2005;19(5):767-84. [Medline].
Callen JP. Cutaneous lupus erythematosus: a personal approach to management. Australas J Dermatol. Feb 2006;47(1):13-27. [Medline].
Huber A, Tuting T, Bauer R, Bieber T, Wenzel J. Methotrexate treatment in cutaneous lupus erythematosus: subcutaneous application is as effective as intravenous administration. Br J Dermatol. Oct 2006;155(4):861-2. [Medline].
Kreuter A, Hyun J, Altmeyer P, Gambichler T. Intravenous immunoglobulin for recalcitrant subacute cutaneous lupus erythematosus. Acta Derm Venereol. 2005;85(6):545-7. [Medline].
Wenzel J, Brahler S, Bauer R, Bieber T, Tuting T. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol. Jul 2005;153(1):157-62. [Medline].
Kreuter A, Tomi NS, Weiner SM, Huger M, Altmeyer P, Gambichler T. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol. Jun 2007;156(6):1321-7. [Medline].
Chang AY, Piette EW, Foering KP, Tenhave TR, Okawa J, Werth VP. Response to Antimalarial Agents in Cutaneous Lupus Erythematosus: A Prospective Analysis. Arch Dermatol. Jul 18 2011;[Medline].

